ArticleJournal of cardiac failure2021
Clinical and Imaging Response to Tumor Necrosis Factor Alpha Inhibitors in Treatment of Cardiac Sarcoidosis: A Multicenter Experience.
Article in Journal of cardiac failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies.The European respiratory journal · 2022Pooled it
- Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review.Journal of the American Heart Association · 2021Pooled it
- Cardiac Sarcoidosis: A Practical Guide for Cardiologists.Current cardiology reports · 2026Review
- Management of Clinical Cardiac Sarcoidosis Isolated to the Heart With Tumor Necrosis Factor-Alpha Inhibitors.JACC. Case reports · 2025Article
- Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.Seminars in respiratory and critical care medicine · 2025Review
- Narrative review of adalimumab for the treatment of cardiac sarcoidosis.Heart rhythm O2 · 2025Review
- Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Immunomodulating and Immunosuppressive Therapy for Virus-Negative Immune-Mediated Myocarditis.Biomedicines · 2024Review
- Sarcoidosis versus Granulomatous and Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency: A Comparative Review.Biomedicines · 2024Review
- The role of infliximab in treating refractory cardiac sarcoidosis. Case series and systematic review of literature.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Cardiac Sarcoidosis-Diagnostic and Therapeutic Challenges.Journal of clinical medicine · 2024Review
- Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients.Respiratory research · 2024Article
- Cardiac sarcoidosis: diagnosis and management.Frontiers in cardiovascular medicine · 2024Review
- Comparison of long-term outcomes in patients with cardiac sarcoidosis treated with different immunosuppressive drugs.American journal of cardiovascular disease · 2024Article
- Clinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis.The American journal of cardiology · 2023Article
- Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.European heart journal · 2023Article
- Assessment of treatment response in cardiac sarcoidosis based on myocardialFrontiers in immunology · 2023Article
- Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system.Frontiers in immunology · 2023Review
- Successful treatment of recurrent cardiac sarcoidosis with the combination of corticosteroid and methotrexate monitored byEuropean heart journal. Case reports · 2022Article
- Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review.Respiratory medicine case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCardiac sarcoidosis (CS) is an increasingly recognized cause of cardiomyopathy; however, data on immunosuppressive strategies are limited. Treatment with tumor necrosis factor (TNF) alpha inhibitors is not well described; moreover, there may be heart failure-related safety concerns.
methodsRetrospective multicenter study of patients with CS treated with TNF alpha inhibitors. Baseline characteristics, treatments, and outcomes were adjudicated.
resultsThirty-eight patients with CS (mean age 49.9 years, 42% women, 53% African American) were treated with TNF alpha inhibitor (30 infliximab, 8 adalimumab). Prednisone dose decreased from time of TNF alpha inhibitor initiation (21.7 ± 17.5 mg) to 6 months (10.4 ± 6.1 mg, P = .001) and 12 months (7.3 ± 7.3 mg, P = .002) after treatment. On pre-TNF alpha inhibitor treatment positron emission tomography with 18-flourodoxyglucose (FDG-PET), 84% of patients had cardiac FDG uptake. After treatment, there was a significant decrease in number of segments involved (3.5 ± 3.8 to 1.0 ± 2.5, P = .008) and maximum standardized uptake value (3.59 ± 3.70 to 0.57 ± 1.60, P = .0005), with 73% of patients demonstrating complete resolution or improvement of cardiac FDG uptake. The left ventricular ejection fraction remained stable (45.0 ± 16.5% to 47.0 ± 15.0%, P = .10). Four patients required inpatient heart failure treatment, and 8 had infections; 2 required treatment cessation.
conclusionsTNF alpha inhibitor treatment guided by FDG-PET imaging may minimize corticosteroid use and effectively reduce cardiac inflammation without significant adverse effect on cardiac function. However, infections were common, some of which were serious, and therefore patients require close monitoring for both infection and cardiac symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.